Literature DB >> 28509092

A case of primary (AL) amyloidosis with predominantly vascular amyloid deposition in the kidney.

Yoichi Murakami1, Soken Hattori2, Fumiko Sugiyama2, Kazuyuki Yoshikawa2, Takeshi Sugiura2, Hideki Matsushima2.   

Abstract

We report a 70-year-old man with primary (AL) amyloidosis with predominantly vascular deposition of amyloid diagnosed by renal biopsy, who was successfully treated using two chemotherapy regimens. There was rapid elevation of the serum creatinine level without remarkable proteinuria or hematuria. Renal histological examination showed some thickened arterial walls with amyloid fibril accumulation, and only a small amount of amyloid deposition in the glomeruli. Immunohistochemical examination was positive for anti-kappa staining. Serum immunoelectrophoresis and immunofixation testing did not show monoclonal proteins, and urine immunoelectrophoresis did not show Bence-Jones proteins. Serum free light chain (FLC) analysis showed that the serum FLC level and FLC kappa/lambda ratio were abnormally high for his renal function. He received two courses of VAD (vincristine, doxorubicin, and dexamethasone), followed by BD (bortezomib and dexamethasone), resulting in a hematologic partial response. Renal amyloidosis with vascular-limited amyloid deposition has few urinary findings. Early diagnosis of this condition is challenging, because kidney biopsies are not usually performed in patients without significant urinary findings. We suggest several currently available methods of achieving earlier detection of this condition.

Entities:  

Keywords:  AL amyloidosis; Bortezomib; VAD; Vascular deposition; Vascular limited

Year:  2014        PMID: 28509092      PMCID: PMC5411632          DOI: 10.1007/s13730-014-0157-7

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  24 in total

1.  Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice.

Authors:  Ingrid I van Gameren; Bouke P C Hazenberg; Johan Bijzet; Martin H van Rijswijk
Journal:  Arthritis Rheum       Date:  2006-06

2.  Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis.

Authors:  Per Westermark; Eva Davey; Karolina Lindbom; Stina Enqvist
Journal:  Acta Histochem       Date:  2006-05-22       Impact factor: 2.479

3.  Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis.

Authors:  M A Duston; M Skinner; R F Meenan; A S Cohen
Journal:  Arthritis Rheum       Date:  1989-01

4.  Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis.

Authors:  Hiroshi Uda; Akira Yokota; Kumiko Kobayashi; Tadao Miyake; Hiroaki Fushimi; Akira Maeda; Osamu Saiki
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

5.  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.

Authors:  Efstathios Kastritis; Ashutosh D Wechalekar; Meletios A Dimopoulos; Giampaolo Merlini; Philip N Hawkins; Vittorio Perfetti; Julian D Gillmore; Giovanni Palladini
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

6.  Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever.

Authors:  C Sungur; A Sungur; S Ruacan; N Arik; U Yasavul; C Turgan; S Caglar
Journal:  Kidney Int       Date:  1993-10       Impact factor: 10.612

7.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Authors:  Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

8.  Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years.

Authors:  J D Neaton; L H Kuller; D Wentworth; N O Borhani
Journal:  Am Heart J       Date:  1984-09       Impact factor: 4.749

9.  A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis.

Authors:  Ying Yao; Su-Xia Wang; You-Kang Zhang; Zhen Qu; Gang Liu; Wan-Zhong Zou
Journal:  Nephrol Dial Transplant       Date:  2012-11-25       Impact factor: 5.992

10.  Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience.

Authors:  M A Duston; M Skinner; T Shirahama; A S Cohen
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

View more
  2 in total

1.  Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.

Authors:  Roberta Fenoglio; Simone Baldovino; Michela Ferro; Savino Sciascia; Gianluca Rabajoli; Giacomo Quattrocchio; Giulietta Beltrame; Carla Naretto; Daniela Rossi; Mirella Alpa; Antonella Barreca; Mario Giulio Papotti; Dario Roccatello
Journal:  J Nephrol       Date:  2020-05-29       Impact factor: 3.902

Review 2.  On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications.

Authors:  Mikhail Inyushin; Astrid Zayas-Santiago; Legier Rojas; Lilia Kucheryavykh
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.